Cytovance® Biologics, Inc. announces completion of first batch in new state-of-the-art 1000L microbial facility
OKLAHOMA CITY, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Cytovance® Biologics, Inc., a leading full-service biopharmaceutical contract manufacturer of mammalian and microbial biologics, announces completion of first batch in new state-of-the-art 1000L microbial facility.
OKLAHOMA CITY, Jan. 15, 2018 (GLOBE NEWSWIRE) -- Cytovance® Biologics, Inc., announces and welcomes Edwin Miranda as Vice President of Quality. Edwin Miranda will be leading the full breadth of Cytovance’s Quality function.
Cytovance Biologics, Inc. announces Bexion Pharmaceuticals Inc. has chosen Cytovance to manufacture the protein componen
OKLAHOMA CITY, Nov. 28, 2017 (GLOBE NEWSWIRE) Cytovance Biologics Inc. has been chosen by Bexion Pharmaceuticals Inc. (Bexion) to manufacture the protein component and active ingredient of Bexion’s first clinical compound, BXQ-350. An ongoing supply of this protein will support Bexion’s continued drug development efforts, including planned Phase II clinical trials.
Cytovance® Biologics Inc., Completes Its First FDA General Inspection Of Oklahoma City, OK Facilities.
Cytovance hosted an unannounced FDA inspection Tuesday, July 11th 2017.
Oklahoma City, OK – (March 14, 2017) Cytovance® Biologics, a leading CDMO who provides unparalleled support to biopharmaceutical companies to move candidate molecules from the bench to commercial manufacturing, announces today that it has received a CMO Leadership Award in three categories.
Oklahoma City, OK – (January 13, 2017) Cytovance® Biologics, Inc., a leading full service biopharmaceutical contract manufacture of mammalian and microbial biologics, today announced the addition of Mike O’Mara as Sr. Vice President of Manufacturing Operations
OncoQuest Initiates Commercial Scale Oregovomab Manufacturing Program for Treatment of Ovarian Cancer
OncoQuest Inc. Signs Agreement with Cytovance for Development of Commercial Scale Antibody Manufacturing, and with Veristat for Clinical Trial Management
OKLAHOMA CITY, OK --(Marketwired - November 29, 2016) - Cytovance® Biologics, Inc., a leading full service contract manufacturer of mammalian and microbial biologics, today announced the addition of Joyce Johnson as Vice President of Human Resources.
Oklahoma City, OK – (September 13, 2016) Cytovance® Biologics, Inc., a leading biopharmaceutical contract manufacturing organization announces the appointment of Jenny Chen to Chief Financial Officer.
Oklahoma City, OK – (August 9, 2016) Cytovance® Biologics, Inc., a leading biopharmaceutical contract manufacturing organization announces the appointment of a Dr. Jesse McCool to its Board of Directors
Cytovance® Biologics, Inc. a leading full service contract manufacturer of mammalian and microbial biologics announces expansion plans for Keystone Expression SystemTM.
BiondVax Pharmaceuticals Ltd. selects Cytovance® Biologics Inc. for the manufacturing of M-001 the universal flu…
Cytovance® Biologics, Inc. announced that it has entered into a Development and Manufacturing Agreement for the production of Phase III batches of a universal flu vaccine, M-001, with BiondVax Pharmaceuticals Ltd. (TASE, NASDAQ: BVXV), a biopharmaceutical company, based in Ness Ziona Israel.
Cytovance® Biologics, Inc., announced today that they have entered into a definitive agreement by which Hepalink USA Inc. will acquire Cytovance® Biologics Inc., a leading biopharmaceutical contract development manufacturing company.
Cytovance® Biologics, Inc., a leading full-service contract development and manufacturer of mammalian and microbial biologics, announces that it has teamed up with NeuroFx to develop and manufacture stem cell derived, cell-free therapy for neurological conditions.
Oklahoma City, OK - Cytovance® Biologics Inc., a leader in the manufacturing of mammalian and microbial biopharmaceuticals announced it has received four CMO Leadership Awards for 2015
Oklahoma City, OK-Cytovance® Biologics, Inc., a leading biopharmaceutical contract manufacturing company is gearing up for The BioInnovation Summit in London, UK February 10-11, 2015. Jesse McCool, Ph.D., will present on one of Cytovance’s open innovation projects, the Keystone Expression System™
Cytovance Biologics, Inc. is pleased to announce the appointment of Seth Fisher as Director of Purification Development in the R&D Services group.